Medical World News® Inside the Practice: CancerNetwork® and Albert H. Kim, MD, PhD, on Treating Brain Tumor Malignancies at the Siteman Cancer Center

Video

CancerNetwork® spoke with Albert H. Kim, MD, PhD, about a new Brain Tumor Center at Siteman, for which he is the inaugural director.

For the latest installment of the Inside the Practice segment of the Medical World News® broadcast, CancerNetwork® spoke with Albert H. Kim, MD, PhD, of the Washington University School of Medicine and Barnes-Jewish Hospital, about the newly established Brain Tumor Center at the Siteman Cancer Center. The center will bring together multidisciplinary specialists in neurosurgery, medicine, radiation oncology, pathology, immunology, otolaryngology, and endocrinology to conduct cutting-edge research

In the interview, Kim talked about a new neuroscience building on the medical campus that will eventually house the center as well as 100 or so laboratories for clinical research.

The center also offers some leading-edge treatment techniques, like proton beam therapy for malignancies in adult and pediatric patients, that may offer options not yet available at other institutions.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.